162162

G00002

ABSTRACT

This invention relates to therapeutic agents for diabetes comprising a 2-(N-cyanoimino)thiazolidine-4-one derivatives represented by formula I or a solvate or a pharmaceutically acceptable salt thereof as an active ingredient:



I

wherein ring A represents a benzene ring, a condensed ring, or a heterocyclic ring, each of which may be substituted by one or more substituents selected from a straight or branched C_1 - C_4 alkyl group, a haloalkyl group, a halogen atom or $-OR^5$,

R^1 represents a single bond, an oxygen atom, a sulfur atom, a methyne group, a straight or branched C_1 - C_4 alkylene or alkenylene group optionally substituted by a phenyl group, R^6-X, X-R^6, X-R^6-X, R^6-X-R^6, -C(=O)-NR^7- or -NR^7-C(=O)-,

R^2 and R^3 are the same or different and each represents a hydrogen atom, a C_1 - C_4 alkyl group, $-OR^8$ or a halogen atom,

R^4 represents a hydrogen atom or a C_1 - C_4 alkyl group,

R^5 represents a hydrogen atom or a C_1 - C_4 alkyl group,

R^6 represents a straight or branched C_1 - C_4 alkylene or alkenylene group,

R^7 represents a hydrogen atom or a C_1 - C_4 alkyl group,

R^8 represents a hydrogen atom, a C_1 - C_4 alkyl group or an aralkyl group,

X represents an oxygen atom or a sulfur atom,

the configuration of the exocyclic methylene group at 5-position of the thiazolidine ring includes both E- and Z-configuration.